Patient Engagement Tech Is PE's Top 2026 Healthcare Play.

Patient engagement technology is the healthcare software category with the highest concentration of simultaneous private equity interest heading into 2026, with at least three large platforms — Main Capital, New Mountain, and Marlin Equity — each building out the space at once rather than waiting for a single winner to consolidate it^[1]. Flexpoint Ford's sale of behavioral-health pharmacy ArtesRx to Linden Capital Partners is the clearest recent proof point, and it shows the category moving from feature to standalone investment thesis^[1]. For mid-market sourcing teams, the practical implication is that the window to build a proprietary target list before a banker formalizes an auction process is closing fast.

Patient engagement technology is software that helps providers, payers, and specialty pharmacies communicate with, activate, and retain patients across a care journey — appointment reminders, medication-adherence tools, remote monitoring, and now agentic AI assistants that triage and follow up without staff intervention.

Three of healthcare software's most active buyers are converging on the same category.

When multiple well-capitalized platforms chase the same thesis at the same time, it is rarely coincidence — it usually means the underlying demand signal has crossed a threshold that justifies competing bets rather than a single roll-up. Main Capital, New Mountain, and Marlin Equity are each reported to be actively targeting patient engagement technology assets in 2026, a pattern more typical of a category inflection than a niche trade^[1].

That matters for two reasons. First, competition for scaled platforms with revenue that already looks like an obvious platform — north of roughly $15 million in recurring software revenue by most sponsor screening standards — is intensifying, which pushes entry multiples up for the handful of assets already visible to bankers. Second, and more useful for lower middle-market sourcing teams, it pushes the smart capital toward smaller, specialized, not-yet-institutional targets before the larger buyers get there.

The category being validated by three separate platforms simultaneously is itself the signal worth acting on, not a reason to wait for the next headline. By the time a fourth or fifth strategic buyer announces a patient engagement acquisition, the assets worth owning at a reasonable multiple will already be gone.

The ArtesRx sale previews where the specialty carve-outs go next.

Flexpoint Ford's sale of ArtesRx — a specialty behavioral-health pharmacy business — to Linden Capital Partners is a case study in how these deals are actually structured^[1]. The driver was not a generic "digital health" thesis; it was the intersection of specialty pharmacy economics and rising mental-health service demand, a combination that produces sticky, recurring revenue tied to a clinical niche rather than a horizontal engagement platform competing on features alone^[1].

That is the pattern sourcing teams should be mapping against: category-specific patient engagement businesses built around a single clinical vertical — specialty pharmacy, oncology adherence, chronic-disease management, behavioral health — tend to graduate from mid-market sponsor to larger strategic buyer once they prove the niche works. Horizontal, feature-competing patient engagement platforms without a defensible clinical wedge are the ones most exposed when a category leader emerges and undercuts on price.

The practical sourcing implication is narrower than "find a patient engagement company." It is: find the specialty pharmacy, behavioral-health, or chronic-disease business that happens to have built proprietary engagement software as a byproduct of serving its niche, because that combination is what closed the ArtesRx deal and is what the next wave of buyers is underwriting.

Agentic AI is the adoption mechanism, not the marketing label.

The reason patient engagement platforms are attracting fresh institutional capital now, rather than five years ago when the category first emerged, is that the software finally does more than send reminders. New software, including agentic AI applications, is directly fueling provider adoption because it automates the follow-up, intake, and adherence check-ins that previously required staff time providers did not have^[1].

This distinction matters in diligence, and it matters more than most sponsors currently treat it. Patient engagement companies that have genuinely embedded agentic AI into clinical workflows — reducing no-show rates, automating medication refill outreach, triaging patient messages — are converting adoption into retained software revenue. Companies still selling engagement as a communications layer on top of an EHR, without an AI-native workflow, are more exposed to commoditization as larger platforms absorb that functionality as a feature.

The claims verification problem is bigger than it looks.

Skepticism toward "AI-enabled" claims is not just a diligence best practice — it tracks a broader shift in how AI claims get scrutinized after close. Securities class-action filings tied to AI claims surged in the first half of 2026, according to reports from Cornerstone Research and NERA, alongside meaningful increases in alleged investor losses and settlement values^[2]. That trend applies most directly to public companies, but the underlying dynamic — boards and management teams facing real financial exposure for overstating what their AI actually does — is exactly why sponsors should demand the same evidentiary standard in private diligence: what does the software automate end-to-end, versus what does it merely flag for a human to act on later. A company that cannot answer that question with a workflow diagram, not a slide, is not AI-native.

Capital committed through 2027 outpaces the number of scalable targets.

The capital side of this equation is not in question. ERS Texas, a public pension fund, has set a pacing plan to commit up to $1 billion in new private equity commitments for fiscal year 2027 — one data point among many institutional allocators continuing to build out private equity exposure even as healthcare software valuations remain elevated^[3].

That capital does not sit idle waiting for a perfect target; it flows toward general partners who can demonstrate a credible pipeline, which is precisely why sourcing capacity — not committed capital — is the binding constraint in this category. Firms with dry powder and no proprietary pipeline end up competing in the same auctions as everyone else, bidding up the handful of assets that come to market through a banker.

The mismatch between committed capital and identifiable targets is the same dynamic explored in the dry powder paradox, and patient engagement tech is a clean current example of it: three large platform buyers, a billion-dollar pension allocation looking for a home, and a category of targets that is still mostly fragmented, founder-run, and off-market.

Valuation discipline is the real gating factor for add-ons.

Patient engagement software resists the clean SaaS multiple math that buyers apply to horizontal enterprise software, because engagement metrics — active-patient counts, adherence rates, message-response rates — do not map cleanly to EBITDA the way ARR does, and revenue is frequently bundled with services or dispensing income rather than pure licensing fees. That gap has been flagged by EisnerAmper's Jennifer Cuello as a persistent source of valuation disagreement between buyers and sellers in lower middle-market deals generally^[4], and it is amplified in patient engagement specifically because the revenue mix is rarely clean.

Consider a representative, illustrative scenario built from the deal pattern visible in the market: a specialty behavioral-health pharmacy generates $22 million in trailing revenue, of which management describes roughly 60 percent as "software and engagement services" and 40 percent as dispensing margin. On first pass, a buyer applying a SaaS-adjacent multiple to the full $22 million would badly overpay, because most of that revenue is not software at all — it is pharmacy margin with a software layer attached. Separating the two before an LOI is the difference between a defensible entry multiple and a renegotiation in exclusivity.

Three concrete diligence questions follow from that scenario, and they generalize across the category:

• What share of reported revenue is software licensing versus pharmacy dispensing, care-management fees, or other services bundled into the same contract?
• Do adherence and engagement metrics correlate with actual reimbursement or retention, or are they vanity metrics disconnected from the P&L?
• How much of current growth is organic software adoption versus one-time implementation or onboarding revenue that will not recur?

Sponsors that answer these before an LOI avoid the valuation-gap renegotiations that kill deals in exclusivity — a risk that rises specifically in categories, like this one, where software and services revenue are entangled.

The objections worth taking seriously.

Two pushbacks come up consistently when this thesis is presented to investment committees, and both deserve a direct answer rather than a dismissal.

The first objection is that "agentic AI in healthcare" is a labeling exercise, not a real demand shift — vendors slapping an AI badge on the same reminder software that has existed for a decade. The rising rate of AI-related securities litigation and the associated increase in alleged losses^[2] is actually evidence against complacency on this point, not for it: scrutiny of unverified AI claims is intensifying across every sector, which means diligence teams that insist on a workflow-level demonstration, rather than a marketing deck, will separate real adoption from relabeling faster than the market at large.

The second objection is that mid-market sponsors cannot compete with New Mountain- or Main Capital-scale capital for these assets. That is true for the scaled platforms those firms are already chasing — but it is precisely why the opportunity for smaller sponsors sits one tier down, in the not-yet-institutional, single-clinical-niche businesses that have not yet crossed the revenue threshold that attracts a $1 billion-plus platform buyer^[1][3]. The mismatch in capital scale is the argument for sourcing earlier, not for standing aside.

Integration determines whether the platform actually holds the multiple.

Sourcing the target is only the first half of the problem; scaling it without breaking the operating model is the second. As patient engagement platforms roll up multiple specialty-focused businesses, HR and operational infrastructure — staffing models, compliance across state pharmacy and behavioral-health licensing, and data integration across disparate clinical systems — become the binding constraint on speed to close the next add-on, a theme Insperity's leadership has emphasized as portfolio companies scale from single-site operators into multi-entity platforms^[5].

That has a direct sourcing implication: targets with clean, centralized HR and compliance infrastructure already in place close faster and integrate cheaper than targets that require building that infrastructure from scratch post-close. Weighting diligence toward operational readiness, not just software architecture, separates add-ons that accelerate a platform from ones that stall it for two quarters while the platform sorts out multi-state licensing.

The CARE filter: a four-part test for sourcing before the auction forms.

A useful shortcut for prioritizing outbound in this category is the CARE filter — four criteria that correlate with both buyer interest and deal cleanliness in patient engagement tech specifically.

• C — Category niche. Does the business serve a defined clinical vertical (specialty pharmacy, behavioral health, chronic disease, oncology adherence) rather than competing as a horizontal communications layer?
• A — AI-native workflow. Is agentic AI embedded in the core product loop — automating follow-up and triage end-to-end — or bolted on as a marketing claim without a demonstrable workflow?
• R — Reimbursement exposure. Is revenue tied to a reimbursement or dispensing mechanism sticky enough to survive a payer renegotiation, and is it cleanly separable from software licensing for valuation purposes?
• E — Exit-ready ownership. Is the company founder-owned or family-controlled with no prior institutional capital and a clean cap table, or does an existing preferred stack complicate a near-term process?

Applying the CARE filter to the illustrative $22 million behavioral-health pharmacy above: it clears Category (specialty behavioral health), clears AI-native if follow-up and refill outreach are genuinely automated rather than flagged, is ambiguous on Reimbursement until the software/dispensing revenue split is verified, and depends entirely on cap-table history for Exit-readiness. That is a three-of-four candidate on paper — worth a direct call, not yet worth a term sheet. Companies that clear all four are the ones a competing platform is already calling.

Building that shortlist manually, deal by deal, across a fragmented and largely off-market category is exactly the kind of proprietary mapping problem a dedicated sourcing engine exists to solve. Owner readiness is worth a closer look on its own terms — many of the best patient engagement targets are still run by the clinicians or technologists who built them, a dynamic covered in more depth in founder-led business sourcing. Getting that first conversation right, before the company has engaged a banker, is often the difference between a proprietary deal and a competitive process.

The broader lesson for 2026 is that healthcare software categories do not stay proprietary for long once three large platforms start building in the same space at once. The firms that source patient engagement targets systematically — against a filter like CARE, ahead of the next reported platform deal — will be buying at 2024 multiples in a market that is repricing toward 2027 expectations.

FAQ: Patient engagement technology PE deals